6′-bromo-3′,4′-dihydro-1′H-spiro[[1,3]dioxolane-2,2′-naphthalene] | 164149-04-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6′-bromo-3′,4′-dihydro-1′H-spiro[[1,3]dioxolane-2,2′-naphthalene]
• 英文别名: 6’-bromo-3’,4’-dihydro-1’H-spiro[[1,3]dioxolane-2,2’-naphthalene]；6'-bromo-3',4'-dihydro-1'H-spiro[[1,3]dioxolane-2,2'-naphthalene]；6-bromo-2-tetralone ethylene ketal；7'-bromospiro[1,3-dioxolane-2,3'-2,4-dihydro-1H-naphthalene]
• CAS: 164149-04-6
• 化学式: C₁₂H₁₃BrO₂
• 分子量: 269.138
• InChiKey: HGNTYOWZYSSTKE-UHFFFAOYSA-N

物化性质

• 沸点：
  353.0±42.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6′-bromo-3′,4′-dihydro-1′H-spiro[[1,3]dioxolane-2,2′-naphthalene] 在 正丁基锂 作用下， 以 水 为溶剂， 生成 6-Methylthio-2-tetralone
  参考文献：
  名称：

  Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials

  摘要：

  A series of potential antimicrobial derivatives possessing bioisosteric replacements for the central oxazolidinone ring found in oxazolidinone antibacterials have been prepared. The design concept involved replacement of the requisite SP3-hybridized stereogenic center found at the 5-position of the oxazolidinone with a nitrogen atom. The synthesis and antibacterial activity of three such ring systems, the benzisoxazolinones, pyrroles, and isoxazolinones is described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.076
• 作为产物：
  描述：

  6-溴-2-四氢萘酮 、 乙二醇 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 以Ca. 100 %的产率得到6′-bromo-3′,4′-dihydro-1′H-spiro[[1,3]dioxolane-2,2′-naphthalene]
  参考文献：
  名称：

  Synthesis, Characterization, and Application of a Cyclic Stilbene Derivative with Simultaneous Two-photon Absorption Character

  摘要：

  摘要 本研究合成了一种新的环状二苯乙烯衍生物--6-(4-(二苯基氨基)苯基)-N,N-二苯基-7,8-二氢萘-2-胺（D2PDN），并对其进行了表征。在甲苯中的荧光量子产率为 89%（在空气中）和 99%（在氩气中）。利用 2P 激发荧光法测定出 700 纳米波长处的双光子（2P）截面为 166 GM。近红外区域的 2P 响应发色团在 0.17、0.28 和 0.53 V 对 Fc0/Fc+ 时具有可逆氧化信号。发现化合物 D2PDN（E*ox = -2.83 V）是一种同时具有 2P 响应的光氧化催化剂。

  DOI：

  10.1246/cl.230388

文献信息

• Carbazolyl-substituted ethanolamines as selective .beta.-.sub.3 agonists
  申请人：Eli Lilly and Company

  公开号：US06140352A1

  公开（公告）日：2000-10-31

  Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

  本文披露了由以下结构式表示的选择性β3肾上腺素能激动剂：##STR1## 上述结构式中的变量在说明书中有定义。还披露了使用这些化合物来激动β3肾上腺素能受体的方法，例如，需要此类治疗的患者，例如需要肥胖或2型糖尿病治疗的患者。
• Selective .beta.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US05786356A1

  公开（公告）日：1998-07-28

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明属于医学领域，特别是涉及治疗2型糖尿病和肥胖的领域。更具体地说，本发明涉及用于治疗2型糖尿病和肥胖的选择性β3肾上腺素受体激动剂。该发明提供了化合物和治疗2型糖尿病的方法，包括给予需要的哺乳动物化合物I和II的方法：##STR1##
• Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
  申请人：Guo Tao

  公开号：US20060111360A1

  公开（公告）日：2006-05-25

  The present invention discloses compounds of Formula I wherein V, W, Y, Z, R 1 , R 2 , R 3 , R 4 , d, m, n, p and r are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

  本发明公开了I式化合物，其中V、W、Y、Z、R1、R2、R3、R4、d、m、n、p和r在此定义，所述化合物是黑色素浓集激素（MCH）的新型拮抗剂，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含这种MCH拮抗剂的药物组合物，以及使用它们治疗肥胖症、代谢紊乱、食欲失调（如暴食）、糖尿病的方法。
• Selective B3 adrenergic agonists
  申请人：——

  公开号：US20020165234A1

  公开（公告）日：2002-11-07

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr; 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: 1

  本发明属于医学领域，特别是用于治疗2型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3受体激动剂，用于治疗2型糖尿病和肥胖症。本发明提供了化合物和治疗2型糖尿病和肥胖症的方法，包括向需要此类化合物的哺乳动物施用式I的化合物：1
• Bicyclic amine derivatives and their use as anti-psychotic agents
  申请人：SmithKline Beech p.l.c.

  公开号：US06008219A1

  公开（公告）日：1999-12-28

  This invention relates to compounds of formula (I) ##STR1## which are useful as modulators of D.sub.3 receptors, in particular as antipsychotic agents.

  本发明涉及式(I)的化合物：##STR1## 其中这些化合物可用作D.sub.3受体的调节剂，特别是作为抗精神病药物。